#1 Clinical Trials Search in Europe

Narsoplimab

Narsoplimab is an investigational drug currently being studied in clinical trials for its potential to treat thrombotic microangiopathies (TMA) associated with hematopoietic stem cell transplantation (HSCT). These trials aim to evaluate the safety, efficacy, and other important aspects of Narsoplimab in both pediatric and adult patients who have developed this serious complication following stem cell transplants.

Table of Contents

What is Narsoplimab?

Narsoplimab, also known by its other name OMS721, is an investigational drug being studied for its potential to treat a serious complication that can occur after certain types of transplants[1][2]. It’s important to understand that as an investigational drug, narsoplimab is still being tested and is not yet approved for widespread use.

What Condition Does Narsoplimab Treat?

Narsoplimab is being developed to treat a condition called hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)[1][2]. Let’s break this down:

  • Hematopoietic stem cell transplant (HSCT): This is a procedure where healthy blood-forming cells are used to replace damaged or diseased cells in the bone marrow.
  • Thrombotic microangiopathy (TMA): This is a serious complication that can occur after a transplant. It involves damage to small blood vessels, which can lead to blood clots and organ damage.

When TMA occurs as a result of a stem cell transplant, it’s referred to as HSCT-TMA. This condition can be life-threatening and currently has limited treatment options, which is why the development of narsoplimab is so important.

Current Clinical Trials

Narsoplimab is currently being studied in clinical trials to evaluate its safety and effectiveness. Two notable studies are:

  1. Pediatric Study: A Phase 2 study is evaluating narsoplimab in children and adolescents (from 28 days to 18 years old) who have high-risk HSCT-TMA[1]. This study aims to understand how well the drug works in younger patients and if it’s safe for them to use.
  2. Expanded Access Program: There’s also a program that allows patients with HSCT-TMA to access narsoplimab before it’s officially approved, based on their doctor’s recommendation[2]. This is sometimes called “compassionate use” and is typically for patients who have no other treatment options.

How Narsoplimab Works

While the exact mechanism isn’t detailed in the provided information, narsoplimab is classified as a biological drug[1]. Biological drugs are typically designed to target specific processes in the body. In this case, narsoplimab likely works by interfering with the processes that lead to blood vessel damage and clotting in HSCT-TMA.

How Narsoplimab is Administered

According to the clinical trial information, narsoplimab is administered at a dose of 4 mg/kg[1]. It’s likely given intravenously (through a vein), though this isn’t explicitly stated in the provided data. The treatment duration in the pediatric study is 8 weeks, with follow-up for up to 52 weeks.

Effectiveness of Narsoplimab

The clinical trials are measuring several outcomes to determine how effective narsoplimab is[1]:

  • Survival rate: They’re looking at how many patients survive for 100 days and 52 weeks after being diagnosed with high-risk HSCT-TMA.
  • Clinical response: This includes improvements in laboratory markers (like platelet count) and clinical benefits (like improved organ function or reduced need for blood transfusions).
  • Overall survival: They’re also tracking how long patients survive after diagnosis.

Safety and Side Effects

As with any drug, especially one still in testing, it’s crucial to monitor for side effects. The clinical trials are carefully tracking any adverse events that occur during treatment[1]. They’re also checking for the development of anti-drug antibodies, which are proteins that the body might produce in response to the drug.

Patient Access to Narsoplimab

While narsoplimab is not yet widely available, there are two ways patients might be able to access it[1][2]:

  1. Clinical trials: Patients who meet the criteria might be able to participate in ongoing studies.
  2. Expanded Access Program: In some cases, patients with HSCT-TMA who have no other treatment options might be able to receive narsoplimab through this program, based on their doctor’s recommendation.

If you think narsoplimab might be appropriate for you or a loved one, it’s important to discuss this with your healthcare provider. They can provide more information about the current status of the drug and whether it might be a suitable option.

Aspect Details
Drug Name Narsoplimab (also known as OMS721)
Condition Studied Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy (HSCT-TMA)
Study Types Phase 2 clinical trial and Expanded Access Program
Patient Population Pediatric patients (28 days to 18 years) and adults with HSCT-TMA
Primary Outcomes 100-day survival rate, safety, efficacy
Secondary Outcomes 52-week survival rate, clinical response, pharmacokinetics, anti-drug antibody presence
Dosage 4 mg/kg in pediatric trial
Treatment Duration 8 weeks with follow-up up to 52 weeks

FAQ

  • What is Narsoplimab? Narsoplimab is an investigational drug being studied for the treatment of thrombotic microangiopathies (TMA) that can occur after hematopoietic stem cell transplantation (HSCT).
  • What condition is Narsoplimab being tested for? Narsoplimab is being tested for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a serious complication that can occur after stem cell transplants.
  • Who can participate in these clinical trials? One of the trials is specifically for pediatric patients aged 28 days to less than 18 years old with high-risk HSCT-TMA. Another trial provides expanded access to patients who may benefit from Narsoplimab based on their physician's judgment.
  • How is Narsoplimab administered in the trials? In the pediatric trial, Narsoplimab is administered at a dose of 4 mg/kg. The exact method of administration is not specified in the provided information.
  • What are the main outcomes being measured in these trials? The trials are measuring several outcomes, including survival rates at 100 days and 52 weeks after HSCT-TMA diagnosis, safety through monitoring of adverse events, clinical response to the treatment, and the presence of anti-drug antibodies.

Ongoing Clinical Trials on Narsoplimab

  • Study of Narsoplimab for Children with High-Risk Blood Vessel Damage After Stem Cell Transplant

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany The Netherlands Spain

Glossary

  • Thrombotic Microangiopathy (TMA): A condition characterized by small blood clots forming in small blood vessels throughout the body, which can lead to organ damage.
  • Hematopoietic Stem Cell Transplantation (HSCT): A procedure where healthy blood-forming stem cells are transplanted into a patient to replace damaged or diseased bone marrow.
  • HSCT-TMA: Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy, a serious complication that can occur after stem cell transplants.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Anti-drug Antibody (ADA): Antibodies produced by the body's immune system against a therapeutic drug, which can potentially reduce the drug's effectiveness.
  • Expanded Access Program (EAP): A program that allows patients with serious or life-threatening conditions to access investigational drugs outside of clinical trials.
  • CTCAE: Common Terminology Criteria for Adverse Events, a set of criteria for the standardized classification of adverse effects of drugs used in cancer therapy.
  • MedDRA: Medical Dictionary for Regulatory Activities, a standardized international medical terminology used by regulatory authorities in the pharmaceutical industry.

References